
Danish biotech company Orphazyme has applied for legally binding protection from its creditors while it restructures.
The firm hopes that this will mean operations can continue, either partially or entirely, funded by a fundraising round, sale of its assets or a combination of the two, it reports in a stock exchange notification.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app